TC BioPharm (Holdings) plc Income Statement

Ask AI

Financial Statements

In millions of GBP; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Research and development expenses
Administrative expenses
Administrative expenses – costs related to listing
Foreign exchange losses
Other income
Total operating expenses, net
Revenue
Operating expenses:
Research and development expenses
Administrative expenses
Administrative expenses – costs related to preparing for listing
Total operating expenses
Loss from operations
Other income (expense):
Loss on modification of convertible loan
Change in fair value of convertible loan derivatives
Change in fair value of warrant derivatives
Change in fair value of other derivatives
Finance income
Finance costs
Loss before tax
Income tax credit
Net loss for the year and Total comprehensive loss
Basic and diluted loss per share
Change in fair value of derivative liability
Interest expense
Other expense, net
Total other (expense) income, net
Net loss before income taxes
Income tax credit
Net loss
Weighted-average ordinary shares outstanding, basic
Weighted-average ordinary shares outstanding, diluted
Basic net loss per share
Diluted net loss per share

Comments